New @biorxivpreprint! Quite proud to be part of this epic modelling study led by Dr. Melinda Rostal. We show that trans-ovarial transmission (TOT) is required to maintain Rift Valley Fever at local scales. But TOT allows RVF to persist even in the face of high vaccination, suggesting that intense, multi-pronged approaches are required if elimination is the goal.
https://www.biorxiv.org/content/10.1101/2023.10.27.564291v1
Data and #rstats code at https://github.com/ecohealthalliance/RVF_SIR_Model
#InTodaysOJ : the European Union reference laboratory for #RiftValleyFever has be designated
Read the Regulation here 👉 https://europa.eu/!VtrVTq
#ZoonoticDiseases #CattleDiseases #Healthsafety #AnimalHealth
Hi! #introduction to my #science:
My group uses #StructuralBiology (#NMR, #Crystallography, #CryoEM) and cell-based experiments to study protein interactions at the host:pathogen interface.
We study how surface #proteins of Gram-positive bacteria, mainly TIE proteins (chemical harpoons) and M proteins of #GroupAStrep, interact with extracellular matrix and host cells.
Our other interest is the #RiftValleyFever phlebovirus NSs protein. Also dabble in protein engineering and tagging.
RT @HorizonEU: 🆕 #RiftValleyFever call for funding by @CEPIvaccines sees the day with €35 M💶 mobilised from #HorizonEU to boost 🚀 research & advance the development of innovative vaccines 💉 against this viral disease.
Find out more here! 👉https://research-and-innovation.ec.europa.eu/news/all-research-and-innovation-news/eu-and-cepi-provide-funding-development-vaccine-against-rift-valley-fever-2022-09-16_en
🐦🔗: https://nitter.eu/EUScienceInnov/status/1571765872221655040
Research and innovation news alert: €35 million in financial support will be provided by Horizon Europe, the EU’s research and innovation programme, and up to €50 million in total will be made available by CEPI